Abstract
277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have